Patents Assigned to VITAERIS INC.
-
Publication number: 20240124573Abstract: Novel therapeutic protocols are provided relating to the use of an anti-IL-6 antibody, e.g., Clazakizumab, in order to prevent, stabilize, reduce or arrest antibody mediated rejection responses in patients receiving solid organ transplants, e.g., patients receiving transplanted kidney, heart, liver, lungs, pancreas, intestines or combinations of any of the foregoing. Also novel therapeutic protocols are provided pertaining to the use of an anti-IL-6 antibody, e.g., Clazakizumab, as part of a desensitization protocol for treating highly sensitized subjects waiting for and/or after allograft transplants, e.g., patients who are to receive solid organ transplants, e.g., kidney, heart, liver, lungs, pancreas, intestines, skin or combinations of any of the foregoing. The foregoing treatments may be effected in combination with one or more other immunosuppressant regimens or other desensitization procedures.Type: ApplicationFiled: August 10, 2023Publication date: April 18, 2024Applicants: VITAERIS, INC., CEDARS-SINAI MEDICAL CENTERInventors: Kevin CHOW, Edward CHONG, Nuala MOONEY, Julien LION, Stanley C. JORDAN
-
Patent number: 11827700Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making the anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.Type: GrantFiled: November 11, 2020Date of Patent: November 28, 2023Assignee: Vitaeris Inc.Inventors: Leon F. Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, Ethan W. Ojala, Brian R. Kovacevich, John A. Latham, Jeffrey T. L. Smith
-
Publication number: 20230174640Abstract: The present disclosure relates to uses of an anti-IL-6 antibody, e.g., clazakizumab in order to prevent, stabilize, reduce, or otherwise treat acute or chronic respiratory distress syndrome (ARDS or CRDS) and symptoms thereof such as lung damage, and also to treat cytokine storm syndrome, in patients with or suspected of having a bacterial, viral, or fungal infection, such as a coronavirus infection, e.g., COVID-19, SARS, MERS, or another bacterial or viral infection which may cause acute or chronic respiratory distress syndrome or cytokine storm syndrome.Type: ApplicationFiled: March 17, 2021Publication date: June 8, 2023Applicant: Vitaeris Inc.Inventors: Kevin Chow, Edward Chong, Bonnie Lonze, Robert Montgomery
-
Patent number: 10913794Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.Type: GrantFiled: November 17, 2017Date of Patent: February 9, 2021Assignee: VITAERIS INC.Inventors: Leon F. Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, Ethan W. Ojala, Brian R. Kovacevich, John A. Latham, Jeffrey T. L. Smith
-
Patent number: 10875917Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other coagulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al.Type: GrantFiled: September 14, 2018Date of Patent: December 29, 2020Assignee: VITAERIS, INC.Inventor: Jeffrey T. L. Smith
-
Patent number: 10800841Abstract: Methods of treating individuals with autoimmune conditions characterized by elevated IL-6 levels comprising the administration of anti-IL-6 antibodies or antibody fragments are provided.Type: GrantFiled: September 13, 2017Date of Patent: October 13, 2020Assignee: VITAERIS, INC.Inventors: Leon Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, Ethan W. Ojala, John Latham, Brian R. Kovacevich, Jeffrey T. L. Smith
-
Patent number: 10787511Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.Type: GrantFiled: April 2, 2018Date of Patent: September 29, 2020Assignee: VITAERIS INC.Inventor: Jeffrey T. L. Smith
-
Patent number: 10787507Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other cogulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al.Type: GrantFiled: February 22, 2018Date of Patent: September 29, 2020Assignee: VITAERIS INC.Inventor: Jeffrey T. L. Smith